Program
Alprazolam
Also written as “Alprazolam Extended-Release 3 mg Tablets”, “Staccato alprazolam” and “alprazolam XR”.
Its studies are mostly in Anxiety Disorders · Panic Disorder · Seizures · Epilepsy · Asthma, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 120 open or running | phase 4since Mar 5, 2008 | Oct 26, 2005 | none ahead |
| Teva Pharmaceutical Industries | 60 open or running | phase 1since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| GlaxoSmithKline | 30 open or running | phase 1since Nov 28, 2012 | Nov 28, 2012 | none ahead |
| Novartis | 20 open or running | phase 1since Jun 2, 2009 | Jun 2, 2009 | none ahead |
| Orion Corporation, Orion Pharma | 20 open or running | phase 1since Apr 8, 2009 | Apr 8, 2009 | none ahead |
| Nova Pneuma | 10 open or running | phase 1since Jan 17, 2008 | Jan 17, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Oct 26, 2005.
- Mar 5, 20083 phase 4 studies in Panic DisorderViatris · NCT00635531, NCT00635076, NCT00634790
- Mar 28, 20083 phase 1 studies in HealthyViatris · NCT00647894, NCT00650299, NCT00647634
- Dec 16, 2008Phase 1 study in PharmacokineticsViatris · NCT00810316 · 24 enrolled · Mexico
- Jan 26, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00830024, NCT00829426
- Mar 10, 2009Phase 1 study in HealthyViatris · NCT00860119 · 23 enrolled · India
- Mar 18, 20092 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT00865761, NCT00865657
- Apr 8, 2009Orion Corporation, Orion Pharma's first studies: 2 phase 1 studies in HealthyNew to Orion Corporation, Orion PharmaOrion Corporation, Orion Pharma · NCT00878865, NCT00878514
- Jun 2, 2009Novartis's first studies: 2 phase 1 studies in Anxiety DisordersNew to NovartisNovartis · NCT00913341, NCT00912145
- Jan 7, 2010Phase 1 study in HealthyViatris · NCT01046162
- Aug 23, 20102 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT01188057, NCT01188031
- Apr 5, 2011Phase 1 study in Healthy SubjectsViatris · NCT01330472 · 16 enrolled · Singapore
- Nov 28, 2012GlaxoSmithKline's first study: phase 1 study in Anxiety DisordersNew to GlaxoSmithKlineGlaxoSmithKline · NCT01853956 · 28 enrolled
- Dec 6, 20122 phase 1 studies in Anxiety DisordersGlaxoSmithKline · NCT01745575, NCT01745562
- Aug 17, 2026Phase 4 study in Healthy Non-dependent, Recreational Sedative UsersViatris · NCT07777965 · 44 enrolled · United States
TargetBeta
“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule
Other programs on the same 16 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Midazolamrule | Pfizer | phase 4 | 96 |
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 36 |
| brexanolonerule | Supernus Pharmaceuticals | phase 4 | 14 |
| Diazepamrule | Acorda Therapeutics | phase 3 | 9 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07777965Healthy Non-dependent, Recreational Sedative Users · United States | 4 | Completed | Viatris | Aug 31, 2026 | 44 |
| NCT01745575Anxiety Disorders | 1 | Completed | GlaxoSmithKline | Apr 5, 2010 | 26 |
| NCT01745562Anxiety Disorders | 1 | Completed | GlaxoSmithKline | Dec 17, 2010 | 28 |
| NCT01853956Anxiety Disorders | 1 | Completed | GlaxoSmithKline | Dec 10, 2010 | 28 |
| NCT01330472Healthy Subjects · Singapore | 1 | Completed | Viatris | Jun 2011 | 16 |
| NCT01188057Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Aug 2006 | 40 |
| NCT01188031Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2006 | 40 |
| NCT01046162Healthy | 1 | Withdrawn | Viatris | Jul 22, 2010 | 0 |
| NCT00913341Anxiety Disorders | 1 | Completed | Novartis | Nov 1991 | 30 |
| NCT00912145Anxiety Disorders | 1 | Completed | Novartis | Feb 1996 | 26 |
| NCT00878865Healthy · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Jun 2009 | 18 |
| NCT00878514Healthy · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Jun 2009 | 18 |
| NCT00865761Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2005 | 40 |
| NCT00865657Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2005 | 40 |
| NCT00860119Healthy · India | 1 | Completed | Viatris | Oct 2009 | 23 |
| NCT00830024Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jun 2005 | 36 |
| NCT00829426Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jun 2005 | 32 |
| NCT00810316Pharmacokinetics · Mexico | 1 | Completed | Viatris | Nov 2008 | 24 |
| NCT00650299Healthy · United States | 1 | Completed | Viatris | Aug 2004 | 21 |
| NCT00647634Healthy · United States | 1 | Completed | Viatris | Aug 2004 | 21 |
| NCT00647894Healthy · United States | 1 | Completed | Viatris | Jan 2005 | 24 |
| NCT00635531Panic Disorder · United States | 4 | Terminated | Viatris | 16 | |
| NCT00635076Panic Disorder · United States | 4 | Terminated | Viatris | 3 | |
| NCT00634790Panic Disorder · United States | 4 | Terminated | Viatris | 49 | |
| NCT00603980Abuse Liability of Staccato Alprazolam · United States | 1 | Completed | Nova Pneuma | Jan 2009 | 31 |
| NCT00245609Dental Anxiety · Germany, United Kingdom | 2 | Completed | Viatris | 90 |
How it is read
Names in the registry
- “Alprazolam”, 10 entries
- “Alprazolam Extended-Release 3 mg Tablets”, 4 entries
- “Staccato alprazolam”, 3 entries
- “alprazolam XR”, 3 entries
- “Staccato Alprazolam”, 2 entries
Conditions, from the studies’ own filings
- Anxiety Disorders, 5 studies
- Panic Disorder, 3 studies
- Seizures, 2 studies
- Epilepsy, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.